Skip to main content

Opiant Pharmaceuticals, Inc.

OPNTDelisted Mar 2, 2023
Industry
Pharmaceutical Preparations
SEC CIK
0001385508

Opiant Pharmaceuticals, Inc. was delisted on Mar 2, 2023; its insiders filed their last Form 4 on Mar 3, 2023; 37 institutions reported holding it in 13F filings for Q4 2022, worth $43.2M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Opiant Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Opiant Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Opiant Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Skolnick PhilChief Scientific Officer0Mar 3, 20230
Collard Craig ADirector0Mar 3, 20230
Lorianne Masuoka K.Director0Mar 3, 20230
O'Toole David DChief Financial Officer0Mar 3, 20230
Sinclair MichaelDirector, 10% Owner0Mar 3, 20230
Daly Richard JDirector0Mar 3, 20230
Crystal RogerChief Executive Officer0Mar 3, 20230
Silver Gabrielle AlisonDirector0Mar 3, 20230
MacDougall Ann L.Director0Mar 3, 20230
Thomas Thomas T.Director0Mar 3, 20230
Ellison Mark Jason HeathChief Development Officer0Mar 3, 20230
Gorman BrianOther: General Counsel0Mar 3, 20230
Ruth Matthew R.Chief Commercial Officer0Mar 3, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 16, 2021 (view filing)Aug 16Same dayO'Toole David DChief Financial OfficerPPurchase+600$15.38+$9.23K+2.6%23.8K after
Aug 20, 2021 (view filing)Aug 191 dayThomas Thomas T.DirectorSSale−1.00K$16.22−$16.2K−14.3%6.00K after2 lots
Aug 25, 2021 (view filing)Aug 23-252 daysSinclair MichaelDirector, 10% OwnerSSaleCommon Stock, par value $0.001 per share−150.0K$15.71−$2.36M−51.0%144.1K after3 lots
Sep 1, 2021 (view filing)Aug 311 dayRuth Matthew R.Chief Commercial OfficerPPurchase+2.00K$17.34+$34.7K+13.3%17.0K after
Sep 9, 2021 (view filing)Sep 72 daysThomas Thomas T.DirectorSSale−822$18.00−$14.8K−11.0%6.65K after
Sep 13, 2021 (view filing)Sep 103 daysCollard Craig ADirectorPPurchase+9.58K$18.18+$174.1K+239.4%13.6K after
Sep 14, 2021 (view filing)Sep 14Same dayGorman BrianOther: General CounselPPurchase+1.31K$19.04+$25.0K+6.5%21.6K after2 lots
Sep 15, 2021 (view filing)Sep 132 daysCollard Craig ADirectorPPurchase+2.50K$18.13+$45.3K+18.4%16.1K after
Sep 15, 2021 (view filing)Sep 141 dayO'Toole David DChief Financial OfficerPPurchase+200$19.12+$3.82K+0.8%24.0K after2 lots
Sep 16, 2021 (view filing)Sep 16Same dayCrystal RogerChief Executive OfficerPPurchaseCommon Stock par value $0.001+100$23.44+$2.34K+2.0%5.10K after
Sep 16, 2021 (view filing)Sep 142 daysThomas Thomas T.DirectorSSale−1.57K$19.37−$30.4K−16.2%8.11K after3 lots
Sep 23, 2021 (view filing)Sep 21-222 daysThomas Thomas T.DirectorSSale−1.57K$24.54−$38.4K−13.1%10.4K after3 lots
Jan 12, 2022 (view filing)Jan 102 daysCrystal RogerChief Executive OfficerSSale−1.06K$30.49−$32.3K−1.3%80.5K after
Jan 12, 2022 (view filing)Jan 102 daysSkolnick PhilChief Scientific OfficerSSale−385$30.49−$11.7K−1.6%24.0K after
Jan 12, 2022 (view filing)Jan 102 daysO'Toole David DChief Financial OfficerSSale−432$30.60−$13.2K−1.2%35.6K after
Jan 27, 2022 (view filing)Jan 27Same dayCrystal RogerChief Executive OfficerSSale−2.00K$26.15−$52.2K−2.5%78.5K after
Jan 27, 2022 (view filing)Jan 27Same daySkolnick PhilChief Scientific OfficerSSale−1.52K$26.19−$39.8K−6.3%22.4K after
May 16, 2022 (view filing)May 133 daysMacDougall Ann L.DirectorPPurchase+3.00K$10.93+$32.8K+12.9%26.2K after
May 16, 2022 (view filing)May 133 daysCollard Craig ADirectorPPurchase+3.69K$10.49+$38.7K+21.3%21.0K after
May 17, 2022 (view filing)May 161 dayCollard Craig ADirectorPPurchase+27.1K$13.54+$367.6K+129.5%48.1K after
May 17, 2022 (view filing)May 161 daySilver Gabrielle AlisonDirectorPPurchase+2.50K$13.29+$33.2K+13.3%21.3K after
Jun 6, 2022 (view filing)Jun 24 daysGorman BrianOther: General CounselSSale−1.15K$13.52−$15.5K−3.4%32.4K after
Jun 6, 2022 (view filing)Jun 2-34 daysSinclair MichaelDirector, 10% OwnerSSale−20.0K$13.73−$274.6K−28.9%49.2K after2 lots
Jun 8, 2022 (view filing)Jun 6-72 daysSinclair MichaelDirector, 10% OwnerSSale−8.49K$12.93−$109.8K−17.2%40.7K after2 lots
Jun 13, 2022 (view filing)Jun 94 daysSinclair MichaelDirector, 10% OwnerSSale−7.90K$12.25−$96.7K−19.4%32.8K after
Jun 13, 2022 (view filing)Jun 10-133 daysCollard Craig ADirectorPPurchase+5.70K$11.10+$63.3K+11.8%53.8K after2 lots
Jun 15, 2022 (view filing)Jun 13-152 daysSinclair MichaelDirector, 10% OwnerSSale−13.6K$10.96−$149.2K−41.5%19.2K after3 lots
Jul 15, 2022 (view filing)Jul 141 dayCrystal RogerChief Executive OfficerSSale−2.25K$11.11−$25.0K−2.6%82.9K after
Jul 15, 2022 (view filing)Jul 141 dayGorman BrianOther: General CounselSSale−691$11.16−$7.71K−2.0%33.7K after
Jul 15, 2022 (view filing)Jul 141 daySkolnick PhilChief Scientific OfficerSSale−627$11.85−$7.43K−2.6%23.8K after
Jul 15, 2022 (view filing)Jul 141 dayO'Toole David DChief Financial OfficerSSale−779$11.10−$8.65K−2.1%36.8K after
Jul 21, 2022 (view filing)Jul 201 dayRuth Matthew R.Chief Commercial OfficerSSale−1.08K$10.62−$11.5K−3.5%29.9K after
Jan 5, 2023 (view filing)Jan 5Same dayCrystal RogerChief Executive OfficerSSale−5.03K$20.20−$101.6K−6.1%77.9K after
Jan 5, 2023 (view filing)Jan 5Same daySkolnick PhilChief Scientific OfficerSSale−1.42K$20.20−$28.7K−6.0%22.4K after
Jan 5, 2023 (view filing)Jan 5Same dayGorman BrianOther: General CounselSSale−1.31K$20.20−$26.5K−3.9%32.4K after
Jan 5, 2023 (view filing)Jan 5Same dayO'Toole David DChief Financial OfficerSSale−1.60K$20.20−$32.3K−4.3%35.2K after
Jan 5, 2023 (view filing)Jan 5Same dayEllison Mark Jason HeathChief Development OfficerSSale−1.81K$20.20−$36.5K−8.3%19.8K after
Jan 9, 2023 (view filing)Jan 9Same dayCrystal RogerChief Executive OfficerSSale−1.18K$20.20−$23.9K−1.5%76.7K after
Jan 9, 2023 (view filing)Jan 9Same daySkolnick PhilChief Scientific OfficerSSale−369$20.20−$7.45K−1.6%22.0K after
Jan 9, 2023 (view filing)Jan 9Same dayEllison Mark Jason HeathChief Development OfficerSSale−469$20.20−$9.47K−2.4%19.4K after
Jan 9, 2023 (view filing)Jan 9Same dayO'Toole David DChief Financial OfficerSSale−415$20.20−$8.38K−1.2%34.8K after
Jan 31, 2023 (view filing)Jan 274 daysO'Toole David DChief Financial OfficerSSale−541$20.26−$11.0K−1.6%34.2K after
Jan 31, 2023 (view filing)Jan 274 daysSkolnick PhilChief Scientific OfficerSSale−480$20.26−$9.72K−2.2%21.5K after
Jan 31, 2023 (view filing)Jan 274 daysGorman BrianOther: General CounselSSale−444$20.26−$9.00K−1.4%32.0K after
Jan 31, 2023 (view filing)Jan 274 daysEllison Mark Jason HeathChief Development OfficerSSale−610$20.26−$12.4K−3.2%18.8K after
Jan 31, 2023 (view filing)Jan 274 daysCrystal RogerChief Executive OfficerSSale−1.36K$20.26−$27.5K−1.8%75.3K after